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INTRODUCTION:  Pancreatic  giant  cell  tumors  are  rare,  with  an  incidence  of  less  than  1% of  all  pancreatic
tumors.  Osteoclastic  giant cell  tumor  (OGCT)  of the  pancreas  is  one  of  the  three  types  of PGCT, which  are
now  classiﬁed  as undifferentiated  carcinoma  with  osteoclast-like  giant  cells.
PRESENTATION OF  CASE:  The  patient  is  a 57 year  old woman  who  presented  with  a  3 week  history  of
epigastric  pain  and  a palpable  abdominal  mass.  Imaging  studies  revealed  an  18 cm  × 15  cm soft  tissue
mass  with cystic  components  which  involved  the  pancreas,  stomach  and  spleen.  Exploratory  laparotomy
with  distal  pancreatectomy,  partial  gastrectomy  and  splenectomy  was  performed.  Histology  revealed
undifferentiated  pancreatic  carcinoma  with  osteoclast-like  giant  cells  with  production  of  osteoid  and
glandular  elements.
DISCUSSION:  OGCT  of the pancreas  resembles  benign-appearing  giant cell  tumors  of bone, and  contain
osteoclastic-like  multinucleated  cells  and  mononuclear  cells.  OGCTs  display  a less  aggressive  course  with
slow  metastasis  and  lymph  node  spread  compared  to  pancreatic  adenocarcinoma.  Due to  the  rarity  of  the
cancer,  there  is  a lack  of prospective  studies  on  treatment  options.  Surgical  en-bloc  resection  is currently
considered  ﬁrst  line  treatment.  The  role  of  adjuvant  therapy  with  radiotherapy  or  chemotherapy  has  not
been  established.
CONCLUSION:  Pancreatic  giant  cell  tumors  are  rare  pancreatic  neoplasms  with  unique  clinical  and  patho-
logical  characteristics.  Osteoclastic  giant  cell  tumors  are  the  most  favorable  sub-type.  Surgical  en bloc
resection  is  the  ﬁrst line  treatment.  Long-term  follow-up  of  patients  with  these  tumors  is  essential  to
compile  a  body  of  literature  to help  guide  treatment.
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. Introduction
Pancreatic neoplasms are relatively common gastrointestinal
alignancies, with the most common type being adenocarcinoma
f the pancreas. However there are several types of pancreatic can-
er that are much less common, including pancreatic giant cell
umors (PGCT) which are rare non-endocrine tumors of the pan-
Open access under CC BY-NCreas with an incidence of less than 1% of all pancreatic tumors.1
hey were ﬁrst described in 1954 by Sommers and Meissner.2
here are three types of pancreatic giant cell tumors: osteoclastic,
Abbreviations: CEA, carcinoembryonic antigen; cGy, centigray; CT, computerized
omography;  GCT, giant cell tumor; MV,  megavolts; OGCT, osteoclastic giant cell
umor; PD, pancreaticoduodenectomy; PR, pancreatic resection; PGCT, pleomorphic
iant  cell tumor; RFA, radio frequency ablation; RT, radiotherapy.
∗ Corresponding author. Tel.: +1 806 743 2370; fax: +1 806 743 1475.
E-mail addresses: wudneh.temesgen@ttuhs.edu (W.M.  Temesgen),
itchel.wachtel@ttuhsc.edu (M.  Wachtel), Sharmila.dissanaike@ttuhsc.edu
S.  Dissanaike).
1 Tel.: +1 806 743 2169; fax: +1 806 743 2117.
2 Tel.: +1 806 743 2460; fax: +1 806 743 2113.
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ttp://dx.doi.org/10.1016/j.ijscr.2014.01.002ed  by  Elsevier  Ltd  on  behalf  of  Surgical  Associates  Ltd.  
pleomorphic, and mixed; however since 2010, the World Health
Organization has grouped them together as undifferentiated car-
cinoma with osteoclast- like giant cells.3,4 The osteoclastic variant
has a better prognosis than the other two  subtypes, as well as pan-
creatic adenocarcinoma.5 Giant cell tumors are also seen in other
organs including the breast, thyroid, parotid, colon, skin, orbit, kid-
ney, heart and soft tissue.1,6
PGCT usually affects patients in the 6th to 7th decade of life,
with an equal male to female ratio.6 PGCT mostly involve the
body and tail of the pancreas, unlike pancreatic adenocarcinoma
which mainly involves the head.6,7 Common clinical presentations
of PGCT are nonspeciﬁc abdominal pain, distension and a palpa-
ble mass, whereas jaundice is the most common presentation of
pancreatic adenocarcinoma. PGCT measures around 5–6 cm at pre-
sentation in 60–80% of cases.3 We  describe the second largest PGCT
reported to date, presenting in an otherwise healthy middle-aged
woman.
2. Presentation of case
ense.A  56-year old previously healthy Caucasian woman who worked
as a sales assistant at a clothing store presented to her primary care
doctor for vague epigastric abdominal pain of 3 weeks duration, a
palpable abdominal mass, bilateral leg swelling and anemia with
  s  Ltd.  Open access under CC BY-NC-ND license.
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cig. 1. CT scan of abdomen and pelvis showing soft tissue mass with multiple ﬂui
rom the tail of pancreas to mid spleen and to the level of left iliac crest.
emoglobin of 7.3 g/dl. Her evaluation included an ultrasound of
he abdomen and pelvis which showed a 16 cm × 14 cm mass that
as largely solid with mixed echotexture and small cystic areas in
he center of the abdomen, with an adjacent mass 11 cm × 9 cm at
he left adnexa. Computed tomography (CT) of the abdomen and
elvis revealed a single 18 cm × 15 cm complex soft tissue mass
ith multiple ﬂuid areas and an area of necrosis. The mass extended
rom the left iliac fossa to the mid  spleen (Figs. 1 and 2). The tail
f the pancreas was effaced and obscured by the mass. There were
nlarged lymph nodes 1.5 cm × 1 cm in size to the left of the aorta
nd at the L2 and L3 level. The patient was referred to a gynecologic
ncologist for possible left ovarian cancer and scheduled for total
bdominal hysterectomy and bilateral salpingo-oophorectomy.
At laparatomy, a large complex mass was found invading into
he stomach, pancreas, mesentery and meso-colon. The general
urgical service was consulted and an oncologic resection of the
ass performed in concert with the gynecologic oncologists. The
ass was smooth-walled with a pseudo-capsule effect and was
ble to be carefully dissected from the adherent structures using
 combination of sharp dissection, electrocautery and harmonic
calpel. The actual site of origin of the tumor was unable to be
etermined during this operation since it invaded several struc-
ures (pancreas, spleen and stomach) and disparate areas of the
etroperitoneum and mesentery. The patient underwent stapled
istal pancreatectomy, partial gastrectomy, splenectomy and total
ig. 2. Images were taken at 400× with 75 gold scale bars. On left Hematoxylin and eosi
ancersous glands invested by inﬂammatory cells including osteoclast-like giant cells.s and areas of necrosis, with poor deﬁnition of the tail of the pancreas. It extends
excision of the mass. Grossly the mass consisted of a multilocu-
lated cystic lesion measuring 24 cm × 16 cm × 10 cm,  with a total
weight of 2.5 kg. The patient’s CA 19-9 was found to be elevated at
392 units/mL one week after surgery.
Histologic examination revealed undifferentiated pancreatic
metaplastic carcinoma with osteoclast-like giant cells with pro-
duction of osteoid and with glandular elements (Figs. 2 and 3).
The hematoxylin and eosin stain images and CKAE1/AE3 immuno-
histochemical stains showed glands invested by inﬂammatory
cells including osteoclast-like giant cells. Initial sampling revealed
only the inﬂammatory cells with osteoclast-like giant cells,
possibly consistent with sarcoma. After extensive sampling, car-
cinomatous foci were identiﬁed whose nature was  elucidated
immunohistochemically. The presence of glands excluded sar-
coma. Immunohistochemical staining was positive for vementin
and negative for epithelial membrane antigen (EMA), consistent
with mesenchymal phenotype. CD34 staining demonstrated lym-
phovascular spread. The mucinous epithelial cells stained for EMA
and keratin. The pancreatic specimen had an initial positive margin.
Her post-operative course was uneventful and she was dis-
charged home on day 4, tolerating a regular diet, ambulating
and with pain controlled on minimal oral hydrocodone and
acetaminophen. A post-operative CT was  performed to complete
the evaluation for metastatic disease, since the pre-operative CT
did not include the chest and was a non-contrast study (Fig. 4).
n stains images; on right are CK AE1/AE3 immunohistochemical stains. They show
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pig. 3. Diffuse region of inﬂammatory cells including osteoclast clike giant cells w
E1/AE3.
ue to the positive pancreatic margin she underwent surgical
e-exploration on day 9, with clearing of the positive pancreatic
argin conﬁrmed by frozen section analysis. Once again she did
ery well and was discharged home three days after this ﬁnal opera-
ion. She underwent a short course of radiation therapy to the area
f previous tumor inﬁltration which had been marked by surgi-
al clips intra-operatively. She was initially treated with a dose of
060 cGy in 17 fractions to her tumor bed using intensity modu-
ated radiation therapy (IMRT) technique with the 6 MV  unit. This
as followed by subsequent boost with a dose of 2880 cGy in 16
ractions, also using IMRT technique with the 6 MV unit. The total
ose was 5940 cGy in 33 fractions. The patient tolerated radia-
ion therapy very well without complications and remains well
 months post-operatively. A follow-up CT scan of abdomen and
elvis is planned one year from initial surgery.
. Discussion
Osteoclastic giant cell tumors (OGCT) resemble benign-
ppearing giant cell tumors of bone, and contain osteoclast-like
ultinucleated cells and mononuclear cells. The histogenesis of
GCT is controversial, with a suggestion of both epithelial and
esenchymal origin. The positive immunohistochemical staining
or CEA and keratin favor epithelial derivation, whereas the pos-
tivity for CD68 and vimentin and negativity of cytokeratin favor
ig. 4. Post operative CT of abdomen and pelvis showing post surgical changes
ith  distal pancreatectomy and splenectomy and with ﬂuid collection around the
ancreas.n right, a single large cancer cell. Osteoclast like giant cells didn’t stain with CK
mesenchymal origin. OGCT have a less aggressive course with slow
metastasis and lymph node spread with a better prognosis com-
pared to pleomorphic giant cell tumors and adenocarcinoma of the
pancreas. The interval to death or disease progression ranges from
4 months to 10 years from initial diagnosis.7
In contrast, pleomorphic giant cell tumor of the pancreas is a
highly anaplastic malignancy with pleomorphic mononuclear and
multinucleated giant cells. The positivity for cytokeratin and neg-
ativity for CD68 and vementin favors their epithelial origin. This
tumor follows an aggressive course with early metastasis and poor
prognosis similar or worse to adenocarcinoma of pancreas. Because
of this signiﬁcant difference in clinical behavior and prognosis, it
is important to identify and distinguish between the subtypes of
PGCT. Unfortunately, due to the rarity of this neoplasm, there is a
lack of large scale studies or individual personal experience with
this tumor. Elevation of tumor markers such as CEA and CA19-9
are less frequent in PGCT than adenocarcinomas8,9 thus rendering
them less useful for diagnosis or monitoring.
The paucity of evidence upon which to base treatment decisions
leads to difﬁculty in determining the optimal multi-disciplinary
approach for each patient. In general, surgical en-bloc resection is
considered the ﬁrst line of treatment7,10 while the role of adjuvant
therapy is unclear. Considering the radio-sensitivity of giant cell
tumors of the bone,11 there is a theoretical beneﬁt of abdominal
radiotherapy for PGCT as well, and this was  the basis for our deci-
sion to proceed with radiotherapy despite an apparent complete
surgical resection. Given the epithelial origin of the mononuclear
neoplastic cells, it may  be reasonable to consider agents such
as gemcitabine in cases of disseminated disease or incomplete
resection.
This is the second largest PGCT ever reported, with the largest
being 24.5 cm.12 The late presentation, minimal symptomatology
and rapid successful recovery of this patient illustrate that despite
the large size of the OGCT, she was physiologically not severely
impaired, in contrast to what would be expected of a patient
with an adenocarcinoma of the pancreas of comparable size – a
situation that almost never arises, due to its much more aggres-
sive nature and tendency to metastasize. This strengthens the
argument for aggressive surgical therapy as ﬁrst line treatment,
since OGCT appears to be primarily a locally invasive tumor, as
opposed to one with a high tendency to metastatic disease. A sum-
mary of the characteristics and treatment of PGCT that have been
described in the recent literature, from 2002 to 2012 is shown in
Table 1.
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Table  1
Summary of pancreatic giant cell tumors described between 2002 and 2012, showing treatment and outcome.
Year of publication Author Number of cases Type of pancreatic giant cell
cancer
Treatment Outcome
200213 Shiozawa 32 Undifferentiated osteoclast like
giant cell
Pancreatic Resection Mean survival of 20.4 months
20049 Zou 19 GCT Inoperable-14, PD-2,
Pancreatic  resection-3
Mean survival of 4 months
200414 Loya 1 Mixed PD Alive at 3 years
200415 Osaka 1 OGCT DP + S + TG Alive at 3 years
200516 Ezenekwe 1 Mixed Inoperable
20063 Lukas 2 Inoperable
200617 Sautot-Vial 1 OGCT PD Overall 26 months of survival
200618 Tezuka 1 Intraductal OGCT PD Alive without recurrence at 22
months
200619 Bauditz 1 Mixed Chemotherapy Continued CT at 13 months
200620 Janes 1 OGCT Palliation Died at 7 months
200821 Layﬁeld 6 PGCT-5, OGCT-1 PD-1
Unresectable-3
Metastasis-2
Alive at 3 months
Died  at 3 months
Lost  follow up
200922 Moore 5 PGCT-3, OGCT-1
Mixed-1
Palliation-3, PD + hepatic
segmentectomy + RFA + RT
PD + chemotherapy
Died  at mean of 12.3 weeks-3
Alive  at 18 months-1
Alive  at 13 months-1 after
resection
200923 Marosh 1 Undifferentiated GCT PD + lymph node resection Died 12 months after resection
20091 Burkadze 1 OGCT Pancreatic resection Free of disease after 4 years
201024 Rauramaa 1 OGCT PD Free of disease after 1.5 years
of resection
20102 Athanasios 1 Pleomorphic GCT En-bloc resection Recurrence at 4 months
20105 Singhal 1 OGCT Pancreatic resection –
20116 Rustagi 1 PGCT PD No recurrence after 20 months
201125 Wada 1 OGCT Pancreatic resection Died after 4 months
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12011 Schaffner 1 OGCT 
201227 Sivanandham 1 OGCT 
. Conclusion
Pancreatic giant cell tumors are rare pancreatic neoplasms with
nique clinical and pathological characteristics. Osteoclastic giant
ell tumors are the most favorable sub-type, and en-bloc resection
s the ﬁrst line of treatment. The roles of chemotherapy and radio-
herapy either as adjuvant or neoadjuvant agents have not been
learly established. Long term follow-up of patients with these rare
umors is essential in order to compile a body of literature to help
uide treatment, since the rarity of this tumor renders prospective
tudies unlikely.
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